Dr. Jamie L. Dargart
Claim this profileProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Expert in Cancer
Expert in Neuroblastoma
53 reported clinical trials
108 drugs studied
About Jamie L. Dargart
Education:
- Obtained MD from the University of Toledo College of Medicine and Life Sciences in 2016.
- Completed Residency in Pediatrics at ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, serving as Chief Resident (2019-2020).
- Finished Fellowship in Pediatric Critical Care Medicine at ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital in 2023.
Experience:
- Currently affiliated with ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderStage IV
MYC positive
MYC negative
Affiliated Hospitals
Clinical Trials Jamie L. Dargart is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Jamie L. Dargart
Clinical Trial Related8 years of experience running clinical trials · Led 53 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments Jamie L. Dargart has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Methotrexate
- Vincristine Sulfate
Breakdown of trials Jamie L. Dargart has run
Cancer
Neuroblastoma
Brain Tumor
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jamie L. Dargart specialize in?
Jamie L. Dargart focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Jamie L. Dargart currently recruiting for clinical trials?
Yes, Jamie L. Dargart is currently recruiting for 20 clinical trials in Toledo Ohio. If you're interested in participating, you should apply.
Are there any treatments that Jamie L. Dargart has studied deeply?
Yes, Jamie L. Dargart has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Jamie L. Dargart?
Apply for one of the trials that Jamie L. Dargart is conducting.
What is the office address of Jamie L. Dargart?
The office of Jamie L. Dargart is located at: ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio 43606 United States. This is the address for their practice at the ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.